Impact of daratumumab on stem cell mobilization and transplant in patient with newly diagnosed multiple myeloma: a real word single-center study

Impact of daratumumab on stem cell mobilization and transplant in patient with newly diagnosed multiple myeloma: a real word single-center study

Not applicable.

Saved in:

Bibliographic Details
Main Authors:	Mauro Passucci, Francesca Fazio, Jacopo Micozzi, Manhaz Shafii Bafti, Giovanni Manfredi Assanto, Alfonso Piciocchi, Maurizio Martelli, Maria Teresa Petrucci
Format:	Article
Language:	English
Published:	PAGEPress Publications 2024-04-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Subjects:	daratumumab stem cell mobilization transplant
Online Access:	https://www.mjhid.org/mjhid/article/view/5631
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center
by: Shuiqing Xu, et al.
Published: (2024-12-01)

Daratumumab
by: Vishnu Gopal, et al.
Published: (2020-01-01)

Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
by: A P Dubey, et al.
Published: (2020-01-01)

Optimal daratumumab-based regimen for patients with newly diagnosed and previously untreated multiple myeloma: systematic review and component network meta-analysis
by: Xiaohua Huang, et al.
Published: (2025-05-01)

Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens
by: Danilo De Novellis, et al.
Published: (2024-07-01)

Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis
by: Hua Jiang, et al.
Published: (2024-12-01)

Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma
by: Luqun Wang, et al.
Published: (2025-05-01)

Restoring sensitivity to daratumumab with all-transretinoic acid in a patient with daratumumab-refractory multiple myeloma: A case report and review of the literature
by: Noa Biran, et al.
Published: (2025-03-01)

Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti‐CD38 Monoclonal Antibodies: A Systematic Review
by: Chia Jie Tan, et al.
Published: (2025-03-01)

A case of fatal hyperammonaemic encephalopathy in a patient with end-stage Multiple Myeloma treated with daratumumab
by: Mauro Passucci, et al.
Published: (2023-01-01)

Meta-analysis of the prognostic efficacy of daratumumab combined with standard therapy in high-risk multiple myeloma
by: Hongmei Zhou, et al.
Published: (2025-12-01)

The Novel Use of Daratumumab in the Treatment of Refractory Autoimmune Pulmonary Alveolar Proteinosis
by: April Strong, et al.
Published: (2025-06-01)

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
by: Hongjie Wang, et al.
Published: (2024-12-01)

Daratumumab for refractory posttransplant autoimmune hemolytic anemia: An option beyond the obvious
by: Sreedhar Jayakrishnan Cherulil, et al.
Published: (2025-01-01)

Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant‐Ineligible Patients With Multiple Myeloma
by: Doris K. Hansen, et al.
Published: (2024-11-01)

Combined Rituximab and Daratumumab Treatment in Difficult-to-Treat Nephrotic Syndrome Cases
by: Andrea Angeletti, et al.
Published: (2024-06-01)

Daratumumab for Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits in Kidney Allograft: A Case Report
by: Zewei Chen, et al.
Published: (2025-02-01)

Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy in vitro
by: Harrison D. Collier-Bain, et al.
Published: (2024-12-01)

Effective treatment with daratumumab in post-HSCT refractory immune-mediated cytopenias: a case report and literature review
by: Xiao-yu Jing, et al.
Published: (2025-08-01)

Bleeding Diathesis Secondary to a Heparin-Like Anticoagulant in a Patient with Multiple Myeloma—A Case Report and Review of Literature
by: Nihar Desai, et al.
Published: (2024-02-01)

Daratumumab-based treatment of monoclonal gammopathy–associated angioedema due to acquired C1-inhibitor deficiency
by: Remy S. Petersen, MD, et al.
Published: (2024-11-01)

MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
by: Francesca Fazio, et al.
Published: (2023-08-01)

Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study
by: Øystein Fluge, et al.
Published: (2025-07-01)

Correction: Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—A clinical pilot study
by: Frontiers Production Office
Published: (2025-08-01)

Treatment of double-refractory multiple myeloma
by: S. V. Semochkin
Published: (2021-09-01)

Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease
by: Prabha Shrestha, et al.
Published: (2023-12-01)

Daratumumab treatment for kidney-involved light chain deposition disease prevents renal function progression: a case report with 3 years of follow-up and review of the literature
by: Xueying Chen, et al.
Published: (2025-01-01)

Visualizing immunotherapy for multiple myeloma worldwide from 2013 to 2023: A bibliometric analysis
by: Jinqiao Li, et al.
Published: (2024-12-01)

Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
by: Barry Paul, et al.
Published: (2025-06-01)

Practice-changing updates on multiple myeloma: highlights from the 2024 ASH annual meeting
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2025-05-01)

First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report
by: E. Amabile, et al.
Published: (2024-01-01)

Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients
by: О. I. Ivakhnenko, et al.
Published: (2024-05-01)

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)

Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries
by: Anas Hamad, et al.
Published: (2024-07-01)

Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury
by: E. Bridget Kim, et al.
Published: (2025-07-01)

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
by: Manisha Bhutani, et al.
Published: (2025-02-01)

Delayed diagnosis of POEMS syndrome, how AI tools can enhance diagnostic accuracy
by: Max Jin, et al.
Published: (2025-06-01)

Corrigendum to “First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report” [Leukemia Research Reports (2024) Volume 22, 100491]
by: E. Amabile, et al.
Published: (2025-01-01)

Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years: A Propensity Score-Matched Study
by: Satoshi Yamasaki, et al.
Published: (2024-11-01)

A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma
by: Noa Biran, et al.
Published: (2025-04-01)